Faeth Therapeutics, Inc. (FTH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Faeth Therapeutics, Inc. (FTH) has a cash flow conversion efficiency ratio of -0.056x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.73 Million) by net assets ($191.19 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Faeth Therapeutics, Inc. balance sheet quality to measure how much of total assets are equity-financed.
Faeth Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Faeth Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Faeth Therapeutics, Inc. cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Faeth Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Faeth Therapeutics, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ODDITY Tech Ltd. Class A Ordinary Shares
NASDAQ:ODD
|
-0.023x |
|
Rashtriya Chemicals and Fertilizers Limited
NSE:RCF
|
0.253x |
|
Nsfocus Information Technology Co Ltd
SHE:300369
|
-0.005x |
|
Lsb Industries Inc
NYSE:LXU
|
0.095x |
|
LIGHTHOUSE PROPERTIES
F:87O
|
N/A |
|
Navient Corp
NASDAQ:NAVI
|
0.073x |
|
CoAsia Microelectronics
TWO:8096
|
-0.504x |
|
IFE Elevators Co Ltd
SHE:002774
|
0.051x |
Annual Cash Flow Conversion Efficiency for Faeth Therapeutics, Inc. (2018–2025)
The table below shows the annual cash flow conversion efficiency of Faeth Therapeutics, Inc. from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Faeth Therapeutics, Inc. worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $18.59 Million | $-20.45 Million | -1.100x | -71.17% |
| 2024-12-31 | $38.39 Million | $-24.67 Million | -0.643x | -30.24% |
| 2023-12-31 | $64.89 Million | $-32.02 Million | -0.493x | -30.75% |
| 2022-12-31 | $103.41 Million | $-39.03 Million | -0.377x | -82.74% |
| 2021-12-31 | $146.51 Million | $-30.26 Million | -0.207x | +81.46% |
| 2020-12-31 | $15.89 Million | $-17.70 Million | -1.114x | -992.43% |
| 2019-12-31 | $-68.66 Million | $-8.57 Million | 0.125x | -35.27% |
| 2018-12-31 | $-53.48 Million | $-10.31 Million | 0.193x | -- |
About Faeth Therapeutics, Inc.
Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune chec… Read more